33 results about "ERBB2 Antibody" patented technology

The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.

The invention belongs to a biomedical technology field. The invention provides an anti-human ErbB2 antibody and ansamitocin conjugate, comprising: substituting lysine at 30 or / and 65 position in a heavy chain variable region of Trastuzumab with a hydrophilic amino acid, and then coupling with ansamitocin (DM1). On basis of maintaining coupling Pharmaceutical activity, a proportion of ansamitocin in a coupling medicament is reduced, thereby reducing toxic and side effect of the coupling medicament. The invention further provides applications of the anti-human ErbB2 antibody and ansamitocin conjugate for preparing antitumor drugs.

This application describes humanized anti-ErbB2 antibodies, and methods of treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.

The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.

The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.

The invention discloses a fusion protein of Her2 antibody and interleukin 2 and application thereof, and belongs to the technical fields of medical science and oncology phymatology. The fusion protein comprises CD16 monoclonal antibody heavy chain signal peptide, ErbB2 antibody heavy chain variable region, a Linker 1, a light chain variable region, a human antibody Fc segment, a Linker 2 and IL-2 mature peptide, and has the amino acid sequence shown as SEQ ID No.1. The fusion protein can inhibit Herceptin resistant breast cancer cell proliferation, and can kill Her2 high-expression breast cancer cells. The invention lays a foundation for clinical application of the fusion protein of the Her2 antibody and the interleukin 2 in the anti-tumor aspect.

An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59 YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and / or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.

An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59 YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.

The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.

The invention discloses an ErbB2 antigen epitope peptide bonded with an E9 antibody. The ErbB2 antigen epitope peptide disclosed by the invention is an antigen epitope peptide respectively named as A1and / or B1, wherein A1 contains amino acid residues as follows: Arg at a site 136 of a sequence 6 in a sequence table, Pro at a site 138, Cys at a site 141, Tyr at a site 142 and Asp at a site 144; and B2 contains amino acid residues as follows: Asn at a site 141 of the sequence 6 in the sequence table, Arg at a site 167, Cys at a site 171, His at a site 172 and Glu at a site 186. Compared with abonding region between chA21 and ErbB2, an ErbB2 antibody, antigen epitope peptide bonded with the ErbB2 antibody and antigen epitope have the advantages that the bonding sequences between E9 and ErbB2 are reduced, and the preparation of new ErbB2 antibody is promoted.

Provided is a method for the prophylaxis or treatment of cancer, comprising administering to a patient in need thereof an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing,wherein A, X, Y, L, D and a are as defined herein.

Provided is binding protein comprising an antigen binding fragment that specifically binds receptor tyrosine-protein kinase ErbB-2 (ErbB2), polynucleotides encoding the binding protein, vectors comprising the polynucleotides, pharmaceutical composition comprising the binding protein as well as methods of using the binding protein. The binding protein can be used for treating a disease or disorder, in which an ErbB2 activity is detrimental or inhibiting growth of ErbB2 positive cells or tumors synergistically with another ErbB2 antibody such as Trastuzumab. The binding protein can also be used for enhancing internalization of an agent or another ErbB2 antibody, for example, Trastuzumab, into ErbB2 positive cells.

The present invention relates to an antibody that specifically binds to ErbB2. The antibody can bind to ErbB2 protein with higher affinity, and has the ability to inhibit the proliferation of SK-BR3 breast cancer cells with high ErbB2 expression and at the same time inhibit the low expression of ErbB2 induced by Heregulin β MCF‑7 breast cancer cell proliferation and other biological activities.

The invention discloses an ErbB2 antigen epitope peptide bonded with an E9 antibody. The ErbB2 antigen epitope peptide disclosed by the invention is an antigen epitope peptide respectively named as A1and / or B1, wherein A1 contains amino acid residues as follows: Arg at a site 136 of a sequence 6 in a sequence table, Pro at a site 138, Cys at a site 141, Tyr at a site 142 and Asp at a site 144; and B2 contains amino acid residues as follows: Asn at a site 141 of the sequence 6 in the sequence table, Arg at a site 167, Cys at a site 171, His at a site 172 and Glu at a site 186. Compared with abonding region between chA21 and ErbB2, an ErbB2 antibody, antigen epitope peptide bonded with the ErbB2 antibody and antigen epitope have the advantages that the bonding sequences between E9 and ErbB2 are reduced, and the preparation of new ErbB2 antibody is promoted.

Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing,wherein A, X, Y, L, D and a are as defined herein.

The present invention relates to anti-ErbB2 antibody variants or antigen-binding fragments thereof, nucleic acid molecules encoding them, and their uses. The antibody variants of the present invention are capable of binding to ErbB2 with high affinity. Therefore, the antibody variants are ability to effectively prevent or treat various cancers with a low amount.

This application describes humanized anti-ErbB2 antibodies, and methods of treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.

The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.

The invention relates to a method for identifying tumors that are responsive to treatment with ANTI-ERBB2 antibodie. Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2 / HER3 and / or HER2 / HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER / 2 / HER1 and / or HER2 / HER3 heterodimers and / or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.

The present invention relates to the combined application of ErbB2 antibody and Saracatinib in the preparation of drugs for treating breast cancer. When the ErbB2 antibody of the present invention is used in combination with Saracatinib, it can synergistically inhibit the growth of ErbB2-positive tumors and has broad application prospects.

The present invention relates to methods of identifying tumors that respond to treatment with anti-ErbB2 antibodies. Tumors responsive to treatment with anti-HER2 antibodies are identified by detecting the presence of HER2 / HER3 and / or HER2 / HER1 protein complexes or HER2 phosphorylation in tumor cell samples. Patients with tumors containing HER / 2 / HER1 and / or HER2 / HER3 heterodimers and / or HER2 phosphorylation are treated with an anti-HER2 antibody, such as rhuMAb 2C4.